We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Diclofenac Potassium Versus Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01019980
Recruitment Status : Terminated (Placebo - Active Drug Not Available. No patients received drug. There are no study results to disclose.)
First Posted : November 25, 2009
Results First Posted : November 19, 2012
Last Update Posted : November 19, 2012
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

The purpose of this study is to assess if a single dose of Diclofenac potassium (0.5 mg/kg) is more or as effective as a single dose of Acetaminophen (10 mg/kg) in the reduction of fever during 2 hours, in the treatment of febrile children with acute upper respiratory infections.

This is a comparative double blind, double dummy, randomized study on the effectiveness of Diclofenac potassium versus Acetaminophen in febrile children with acute upper respiratory tract infections. The patient will be randomized to either group: Group A (Diclofenac potassium (0.5 mg/kg) or Group B (Acetaminophen (10 mg/kg)). A Health Care Professional trained will measure the temperature during 2 hours. During the study period, parents or legal representatives will be invited to fill a survey about the habits and knowledge regarding fever management at home.


Condition or disease Intervention/treatment Phase
Fever Drug: Diclofenac potassium Drug: Acetaminophen Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Comparative Double Blind, Double Dummy, Randomized Study on the Effectiveness of Diclofenac Potassium vs. Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections
Study Start Date : March 2010
Primary Completion Date : March 2010


Arms and Interventions

Arm Intervention/treatment
Experimental: Diclofenac potassium Drug: Diclofenac potassium
Diclofenac potassium
Active Comparator: Acetaminophen Drug: Acetaminophen
Acetaminophen


Outcome Measures

Primary Outcome Measures :
  1. The Reduction of Temperature [ Time Frame: 2 hours ]

Secondary Outcome Measures :
  1. Time to Reach a Reduction of Temperature as 0.5 and 1 °C [ Time Frame: 2 hours ]
  2. Time With a Temperature ≤ 38,4 °C in a Period of 6 Hours [ Time Frame: 6 hours ]
  3. Safety of Diclofenac Potassium Therapy in the Study Period [ Time Frame: 6 hours ]
  4. The Level of Knowledge That Parents or Legal Representatives Have on the Treatment of Fever [ Time Frame: 2 hours ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female outpatients, aged 2 to 6 years presenting tympanic temperature ≥ 38.5 ° C and no greater than 39.5° C, associated with acute upper respiratory tract infections
  • Parents or legal representatives who have provided written informed consent and provided a phone number for the call at end of study

Exclusion Criteria:

  • History of hypersensitivity to any drugs or excipients of the study
  • Any medication, surgical, or medical condition, which might significantly alter the absorption, distribution, metabolism, or excretion of medications
  • Background or suspected hematological disorders, febrile seizures, asthma, peptic ulcer or gastrointestinal bleeding
  • Neurological and hemodynamics disorders
  • Evidence of liver or kidney impairment or heart failure
  • Patients who have received previous treatment with antipyretics; acetaminophen (up to 4 hrs), NSAIDs (up to 6 hrs) or antibiotic therapy (at least 12 hours)
  • Any surgical or medical condition, which in the opinion of the investigator, may place the patient at risk

Other protocol-defined inclusion/exclusion criteria may apply

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01019980


Locations
Venezuela
Hospital de niños "J. M. de los Rios", Distrito Metropolitano
Caracas, Venezuela
Ciudad Hospitalaria Enrique Tejera, Valencia
Estado Carabobo, Venezuela
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
More Information

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01019980     History of Changes
Other Study ID Numbers: CVOL458AVE02
First Posted: November 25, 2009    Key Record Dates
Results First Posted: November 19, 2012
Last Update Posted: November 19, 2012
Last Verified: October 2012

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Antipyretics
fever
diclofenac
acetaminophen
children
acute upper respiratory tract infections

Additional relevant MeSH terms:
Infection
Respiratory Tract Infections
Respiratory Tract Diseases
Acetaminophen
Diclofenac
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action